The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorTongji Hospital
About this trial
Evaluating the long-term therapeutic effects and safety of hydroxychloroquine(compared to glucocorticoid therapy alone) in patients with inflammatory cardiomyopathy--a multicenter randomized controlled study
Eligibility criteria
Qualifiers
Male or female patient aged from 18 to 80 years;
Left ventricular dysfunction [left ventricular ejection fraction (LVEF) <50%] diagnosed by echocardiography (Simpson's biplane) within 30 days before randomization;
Chronic heart failure (lasting >6 months) unresponsive to conventional supportive therapy;
High-sensitivity cardiac Troponin I (hs-cTnI) >26.2 pg/mL and N-terminal-pro-B-type natriuretic peptide (NT-proBNP) >169pg/mL;
Disqualifiers
Age <18 or >80 years;
Acute myocardial infarction occurred within the past month;
Subjects who have undergone cardiac surgery or cerebrovascular accidents within 6 months;
Preparing for heart transplantation;
Trial design
Treatments tested in this trial
- Hydroxychloroquine
- Prednisolone
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov